Patent · US Active

Substituted 2-anilinopyrimidine derivatives as EGFR modulators

US11414401B2 · kind B2 · utility

0Cited by

1References

7Claims

0Family size

Assignees

BETA PHARMA, INC. · US
BETA PHARMA (SHANGHAI) CO., LTD. · CN

Inventors

Jirong Peng · Mequon, US
Michael John Costanzo · Bonney Lake, US
Michael N. Greco · Lansdale, US
Michael Alan Green · Easton, US
Victoria Lynn Wilde · Montclair, US
Don Zhang · Princeton, US

Key dates

Filing date	Mar 16, 2020
Grant date	Aug 16, 2022
Priority date	—
Expiry date	Apr 3, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D471/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

This application discloses novel substituted 2-anilinopyrimidine derivatives, and pharmaceutically acceptable salts, solvates, prodrugs, and compositions thereof, which are useful for the treatment or prevention of diseases or medical conditions mediated by epidermal growth factor receptors (EGFRs), including but not limited to a variety of cancers.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.